A novel approach to profiling bladder cancers uncovers new biological subtypes of the disease, paving the way for enhanced personalized medicine.
A research team led by Dr. Peter Black has taken an important step toward more personalized treatment for aggressive bladder cancer. In a new study published in Nature Communications, the team examined the complete proteome — the full set of proteins — of muscle-invasive bladder cancers (MIBC) before and after chemotherapy.
By analyzing tumour samples from over 100 patients, the researchers identified distinct biological subtypes of MIBC and uncovered protein patterns linked to chemotherapy response and resistance. These findings suggest new ways to predict which patients may benefit from treatment and point to potential protein targets for future drug development.
This proteomics-based approach opens a new frontier in bladder cancer research and could help advance more precise, individualized treatment strategies for patients with this aggressive disease.
Read more here.
